AR055090A1 - Una presentacion farmaceutica de forma de dosificacion de liberacion modificada que comprende un inhibidor de la enzima ciclooxigenasa - Google Patents

Una presentacion farmaceutica de forma de dosificacion de liberacion modificada que comprende un inhibidor de la enzima ciclooxigenasa

Info

Publication number
AR055090A1
AR055090A1 ARP060103141A ARP060103141A AR055090A1 AR 055090 A1 AR055090 A1 AR 055090A1 AR P060103141 A ARP060103141 A AR P060103141A AR P060103141 A ARP060103141 A AR P060103141A AR 055090 A1 AR055090 A1 AR 055090A1
Authority
AR
Argentina
Prior art keywords
presentation
cyclooxygenase
inhibitor
sodium lauryl
lauryl sulfate
Prior art date
Application number
ARP060103141A
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Sukhjeet Singh
Munish Talwar
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR055090A1 publication Critical patent/AR055090A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee una presentacion farmacéutica de liberacion modificada que comprende al menos un inhibidor de la enzima ciclooxigenasa o sus sales, ésteres, profármacos, solvatos, hidratos o derivados farmacéuticamente aceptables como agente activo, con un portador farmacéuticamente aceptable para controlar la liberacion del inhibidor de enzima ciclooxigenasa. La presentacion provee preferentemente una liberacion de no más de aproximadamente 60% del inhibidor de enzima ciclooxigenasa en 1 hora y no menos de aproximadamente 75% del inhibidor de enzima ciclooxigenasa luego de 12 horas cuando se somete a ensayo segun el método de disolucion (1) aquí descrito, empleándose agua destilada con lauril sulfato de sodio al 2,0% como medio de disolucion, o segun el método de disolucion (2) aquí descrito, empleándose buffer de fosfato pH 7,0 con lauril sulfato de sodio al 2,0% como medio de disolucion, o segun el método de disolucion (3) aquí descrito, empleándose ácido clorhídrico 0,001 N con lauril sulfato de sodio al 1,0% como medio de disolucion. Adicionalmente, la composicion farmacéutica de la presente, cuando es sometida a ensayo en un grupo de humanos sanos, preferentemente alcanza una concentracion máxima promedio en plasma (Cmáx) luego de al menos 1 hora a partir de a administracion de la presentacion. También se provee un proceso de preparacion de tales composiciones y métodos profilácticos y/o terapéuticos de uso de tal presentacion.
ARP060103141A 2005-07-20 2006-07-20 Una presentacion farmaceutica de forma de dosificacion de liberacion modificada que comprende un inhibidor de la enzima ciclooxigenasa AR055090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1899DE2005 2005-07-20

Publications (1)

Publication Number Publication Date
AR055090A1 true AR055090A1 (es) 2007-08-08

Family

ID=37669241

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103141A AR055090A1 (es) 2005-07-20 2006-07-20 Una presentacion farmaceutica de forma de dosificacion de liberacion modificada que comprende un inhibidor de la enzima ciclooxigenasa

Country Status (20)

Country Link
US (1) US20100204333A1 (es)
EP (1) EP1906933A2 (es)
JP (1) JP2009501785A (es)
KR (1) KR20080032209A (es)
CN (1) CN101227893A (es)
AR (1) AR055090A1 (es)
AU (1) AU2006271150A1 (es)
BR (1) BRPI0613547A2 (es)
CA (1) CA2614850A1 (es)
CR (1) CR9828A (es)
DE (1) DE202006020331U1 (es)
DK (1) DK200900115U1 (es)
EA (1) EA200800370A1 (es)
MX (1) MX2008000967A (es)
NO (1) NO20080697L (es)
RS (1) RS20080020A (es)
TN (1) TNSN08018A1 (es)
UA (1) UA89684C2 (es)
WO (1) WO2007010559A2 (es)
ZA (1) ZA200801592B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101431992A (zh) * 2006-04-24 2009-05-13 万能药生物有限公司 包含尼美舒利的新型低剂量药物组合物及其制备和用途
RU2463038C2 (ru) 2006-10-17 2012-10-10 Нуво Рисерч Инк. Диклофенаковый гель
US8546450B1 (en) * 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
CN102188386B (zh) * 2010-03-02 2013-09-04 海南葫芦娃制药有限公司 尼美舒利缓释微丸及其制备方法
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
WO2013103390A1 (en) * 2012-01-04 2013-07-11 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US10632087B2 (en) 2012-02-06 2020-04-28 Innovative Med Concepts, LLC. Famciclovir and meloxicam combination therapy for functional somatic syndromes
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
ES2129010B1 (es) * 1997-01-02 2000-01-16 Gold Oscar Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion.
EP1017370B1 (en) 1997-09-11 2003-10-29 Nycomed Danmark ApS MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
IN188720B (es) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
AU718356B2 (en) * 1998-01-12 2000-04-13 Panacea Biotec Limited A parenteral water-miscible non-intensely coloured injectable composition of non-steroidal anit-inflammatory drugs
WO2000004879A1 (en) * 1998-07-24 2000-02-03 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
US6086920A (en) 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
PT1109534E (pt) 1998-09-10 2003-06-30 Nycomed Danmark As Composicoes farmaceuticas de farmacos de libertacao rapida
EP1218889B1 (en) * 1999-09-28 2009-12-02 Panacea Biotec Limited Controlled release compositions comprising nimesulide
IN190018B (es) * 1999-09-28 2003-05-31 Panacea Biotec Ltd
CA2394222A1 (en) 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
WO2001078725A2 (en) 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
IN190963B (es) * 2000-06-20 2003-09-06 Ajanta Pharma Ltd
CA2498798A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
DE602004007315D1 (de) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone

Also Published As

Publication number Publication date
BRPI0613547A2 (pt) 2011-01-18
RS20080020A (en) 2009-05-06
JP2009501785A (ja) 2009-01-22
KR20080032209A (ko) 2008-04-14
CR9828A (es) 2008-07-31
TNSN08018A1 (en) 2009-07-14
MX2008000967A (es) 2008-03-26
AU2006271150A1 (en) 2007-01-25
CA2614850A1 (en) 2007-01-25
ZA200801592B (en) 2009-10-28
UA89684C2 (ru) 2010-02-25
WO2007010559A2 (en) 2007-01-25
DK200900115U1 (en) 2009-10-23
WO2007010559A3 (en) 2007-09-20
EA200800370A1 (ru) 2008-06-30
US20100204333A1 (en) 2010-08-12
CN101227893A (zh) 2008-07-23
NO20080697L (no) 2008-04-18
EP1906933A2 (en) 2008-04-09
DE202006020331U1 (de) 2008-09-18

Similar Documents

Publication Publication Date Title
AR055090A1 (es) Una presentacion farmaceutica de forma de dosificacion de liberacion modificada que comprende un inhibidor de la enzima ciclooxigenasa
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
MX2014001101A (es) Composiciones orales que contienen un ester 17-hydroxyprogesterona y metodos relacionados.
WO2013022783A3 (en) Progesterone containing oral dosage forms and related methods
EA200870368A1 (ru) Антибиотические композиции с модифицированным высвобождением и способ их получения
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
EA201071035A1 (ru) Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
UA94052C2 (uk) Похідні піридазину
CU20130142A7 (es) Preparación de gadobutrol de alta pureza
BR112014010228A8 (pt) inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática
NO20013367L (no) Colchinolderivater som vaskulorskadende midler
PH12017502416A1 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
AR098899A1 (es) Composiciones para el cuidado oral y métodos
EA200970851A1 (ru) Еженедельное введение ингибиторов дипептидилпептидазы
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
NI200700299A (es) Composicion de liberación modificada de al menos una forma de venlafaxina
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
AR065419A1 (es) Metodo para inhibir la proliferacion de celulas tumorales
AR082022A1 (es) Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal
PE20020903A1 (es) Metodo para prevenir la diarrea
BRPI0506710A (pt) composições farmacêuticas de liberação controlada
FR2805462B1 (fr) Nouvelle forme galenique orale a liberation prolongee de la molsidomine
CO5660084A1 (es) Nuevos derivados de fenilheteroalquilamina, proceso para su prepraracion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal